Waisman researchers first to show than an mRNA involved in fragile X syndrome has dual-function in brain development

By Emily Leclerc | Waisman Science Writer

At a Glance

  • A lab at the Waisman Center is the first to show that the mRNA produced by the gene FMR1, which is the causative gene behind fragile X syndrome, is dual-function.
  • Messenger RNA (mRNA) are typically categorized as coding or noncoding, meaning it either makes a protein or it does not. Rarely does an mRNA both make a protein and have a function on its own.
  • The researchers found that FMR1’s mRNA is not only truly dual-function, a first in the neurodevelopmental world, but it also plays an important role in neuron metabolism regulation.
  • The absence of FMR1’s mRNA in fragile X syndrome could be an important contributor to the metabolic deficits seen in fragile X neurons.

For decades, scientists studying fragile X syndrome (FXS) have been focusing on what the FMR1 gene’s protein product does in the brain. Now, researchers at the Waisman Center, have discovered that the gene’s messenger RNA has a critical job of its own, revealing an unexpected new mechanism in the biology of the condition that could redefine how scientists think about gene regulation.

Published in Neuron, the study is the first to show that FRM1 produces a “dual function” messenger RNA (mRNA), one that not only serves as the blueprint for a protein but also performs important cellular functions independently. The research is from the Waisman lab of Xinyu Zhao, PhD, professor of neuroscience, Jenni & Kyle Professor in Novel Neurodevelopmental Diseases, and Vilas Distinguished Achievement Professor at UW–Madison.

Women wearing a white lab coat smiling
Xinyu Zhao, PhD (Photo © Andy Manis)

Zhao and Soraya Sandoval, PhD, former graduate student in Zhao’s lab, discovered that not only does FMR1’s mRNA have both protein coding and noncoding functions, the first mRNA found to be dual-function in the mammalian brains, but it also plays an important role in neuron metabolism regulation.

“This could rewrite textbook entries on gene regulation,” Zhao says.

FXS, a neurodevelopmental disorder that is the most common form of inherited intellectual disability and autism, results from a mutation in the FMR1 gene. FMRP (fragile X messenger ribonucleoprotein), the protein produced by FMR1, has been intensely studied for decades to understand how its loss ultimately causes FXS. But in FXS, FMR1 also stops producing its mRNA.

“DNA gets transcribed to RNA and then that RNA [specifically mRNA] is translated to a protein. We are almost always thinking about the protein itself. We’ve always studied what is the function of the protein not so much the mRNA. Especially because FMR1’s mRNA is known as a coding mRNA,” Sandoval says.

mRNA is a crucial molecule that translates DNA’s genetic instructions into a form that cellular machinery can use to make proteins. Most mRNA are categorized as either coding or noncoding—meaning they produce a protein product or they don’t. Very few mRNA have true dual-functionality where both their protein product and the mRNA itself play a role in cellular processes. Several years ago, while studying the effects of FMRP on neuron metabolism, Sandoval and Zhao noticed something strange that hinted at FMR1’s mRNA dual-functionality.

Woman with a long pony tail and wearing a white tank top
Soraya Sandoval

Sandoval was studying how FMRP regulates metabolism in neurons. To do this, she had two different groups of neurons derived from stem cells. The first were FXS neurons with the mutation in FMR1 that causes FXS, so they had no FMR1 mRNA or FMRP. The second were knockout or KO neurons that retained FMR1 mRNA but did not make FMRP.

“In 2023 we published a paper showing that these FXS neurons had deficits in their mitochondria and therefore metabolism alongside the other symptoms of FXS,” Zhao says. “When Sandoval created these two cell lines to continue to study metabolism, she noticed that the KO neurons did not have the same deficits as the FXS neurons.”

The KO neurons were not making any FMRP, so why did they not have the same deficits as the FXS neurons? “That’s when we started thinking maybe the mRNA itself has a function,” Zhao says.

Sandoval and Zhao found that FMR1’s mRNA has an important noncoding function in metabolism regulation. It joins a very short list of dual-function mRNA in humans and is a first in the mammalian brain. This finding has significant implications as it reveals a new layer of gene regulation that has previously been almost entirely ignored – the function of the mRNA itself, independent of its protein products, Zhao says.

“It is like how drivers normally look at 2D maps for navigation and our paper points out that there is a 3D component that we should be paying attention to,” Zhao says.

Effective and efficient metabolism and energy production relies on the cell’s systems and processes remaining in balance or homeostasis. This is especially true for high-energy and complex cells like neurons. Glycolysis, a crucial metabolic pathway that is the first step in a cell’s energy production system, is typically upregulated or overactive in FXS cells to compensate for deficits in the mitochondria. This disrupts the cell’s overall metabolism and causes it to fall out of homeostasis. FMR1’s mRNA’s newly discovered function is that it balances critical molecules in the glycolysis pathway, preventing upregulation and keeping metabolism stable. This explains why the KO neurons did not display the glycolysis deficits that the FXS neurons had.  

“It is interesting that in this case,” Sandoval says, “wherever there is an absence of the FMRP protein, as long as the mRNA is there, metabolism remains relatively balanced.”

This discovery has important implications for the FXS premutation as well. Carriers of the premutation have a milder version of the FMR1 mutation to where they do not have intellectual disability or developmental delays, but are at risk of several different conditions developing as they age. Premutation carriers have normal or even higher FMR1 mRNA levels but have lower levels of FMRP than individuals without the condition.

Two images of neurons stained green for visualization
Neurons differentiated from human induced pluripotent stem cells. A shows typical control neurons and B shows neurons with the fragile X syndrome mutation. The length of the fragile X neurons is consistently shorter when compared to the control neurons.

“We thought that the small amount of FMRP protein in individuals with the premutation was the reason why they don’t have intellectual disability but now we’re thinking that maybe the mRNA itself is also helping,” Zhao says. “Our study suggests that the presence of the mRNA in premutation carriers may have an important role in terms of neuronal function.”

This newly discovered dual-functionality opens the door for whole new lines of research. Zhao’s next questions are working to continue to lay foundational knowledge about FMR1’s mRNA. She’s first hoping to expand this work into looking at other neuron types as this study only looked at excitatory neurons. Another important step is to do mechanistic studies on the mRNA to determine which specific parts of the molecule are playing important roles.

It also has the potential to change how researchers study genes functions. “I expect our paper will open the eyes of many scientists who study the functions of genes, especially key regulatory genes and disease genes,” Zhao says. “Now they will also want to look into the functions of those mRNAs in disease mechanisms.”

“This really is only the beginning,” Sandoval adds. “There is a lot left to be explored.”

Contributors to the project include Lingjun Li, PhD, professor in the school of pharmacy at UW–Madison, and Melissa Skala, PhD, professor of biomedical engineering at UW–Madison.